TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

EXPAREL

BUPIVACAINE
Approved 2011-10-28
4
Indications
--
Phase 3 Trials
14
Years on Market

Details

Status
Prescription
First Approved
2011-10-28
Routes
INJECTION
Dosage Forms
INJECTABLE, LIPOSOMAL

Companies

Active Ingredient: BUPIVACAINE

EXPAREL Approval History

Loading approval history...

What EXPAREL Treats

1 indications

EXPAREL is approved for 1 conditions since its original approval in 2011. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pain
Source: FDA Label

Drugs Similar to EXPAREL

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACUVAIL
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
Pain
BELBUCA
BUPRENORPHINE HYDROCHLORIDE
1 shared
BDSI
Shared indications:
Pain
BUPRENORPHINE
BUPRENORPHINE
1 shared
WATSON LABS TEVA
Shared indications:
Pain
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
ASPIRIN
1 shared
STEVENS J
Shared indications:
Pain
BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE
1 shared
Hikma
Shared indications:
Pain
BUTORPHANOL TARTRATE PRESERVATIVE FREE
BUTORPHANOL TARTRATE
1 shared
Pfizer
Shared indications:
Pain
BUTRANS
BUPRENORPHINE
1 shared
PURDUE PHARMA LP
Shared indications:
Pain
BYQLOVI
CLOBETASOL PROPIONATE
1 shared
HARROW EYE
Shared indications:
Pain
CALDOLOR
IBUPROFEN
1 shared
CUMBERLAND PHARMS
Shared indications:
Pain
CATAFLAM
DICLOFENAC POTASSIUM
1 shared
AMICI PHARMA
Shared indications:
Pain
COMBOGESIC IV
ACETAMINOPHEN
1 shared
Hikma
Shared indications:
Pain
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
1 shared
INGENUS PHARMS LLC
Shared indications:
Pain
DIFLUNISAL
DIFLUNISAL
1 shared
Teva
Shared indications:
Pain
DIFLUPREDNATE
DIFLUPREDNATE
1 shared
Cipla
Shared indications:
Pain
DILAUDID
HYDROMORPHONE HYDROCHLORIDE
1 shared
Fresenius Kabi
Shared indications:
Pain
DUREZOL
DIFLUPREDNATE
1 shared
Novartis
Shared indications:
Pain
EC-NAPROSYN
NAPROXEN
1 shared
ATNAHS PHARMA US
Shared indications:
Pain
FLECTOR
DICLOFENAC EPOLAMINE
1 shared
IBSA
Shared indications:
Pain
GLYDO
LIDOCAINE HYDROCHLORIDE
1 shared
SAGENT PHARMS INC
Shared indications:
Pain
HYDROCODONE BITARTRATE AND ASPIRIN
ASPIRIN
1 shared
LGM PHARMA
Shared indications:
Pain
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

EXPAREL FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

EXPAREL is indicated to produce postsurgical: Local analgesia via infiltration in patients aged 6 years and older Regional analgesia via an interscalene brachial plexus nerve block in adults Regional analgesia via a sciatic nerve block in the popliteal fossa in adults Regional analgesia via an adductor canal block in adults EXPAREL contains bupivacaine, an amide local anesthetic, and is indicated to produce postsurgical: Local analgesia via infiltration in patients aged 6 years and older . Regional analgesia via an interscalene brachial plexus nerve block in adults . Regional analgesia via a s...

EXPAREL Patents & Exclusivity

Latest Patent: Jul 2044
Exclusivity: Nov 2026

Patents (96 active)

US12318483 Expires Jul 2, 2044
US12370142 Expires Jul 2, 2044
US12251468 Expires Jul 2, 2044
US12156940 Expires Jul 2, 2044
US12226610 Expires Feb 2, 2043
US11918565 Expires Feb 2, 2043
US11931459 Expires Mar 17, 2042
US11452691 Expires Jan 22, 2041
US11819575 Expires Jan 22, 2041
US11033495 Expires Jan 22, 2041
+ 86 more patents

Exclusivity

I-929 Until Nov 2026
I-929 Until Nov 2026
I-929 Until Nov 2026
I-929 Until Nov 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.